Dow Jones
36 117,38 +62,95 (+0,17 %) Nasdaq
14 339,99 +193,28 (+1,37 %) Nikkei 225
32 336,22 -522,09 (-1,59 %) EUR/USD
1,0787 -0,0010 (-0,10 %) HANG SENG
16 294,00 -51,89 (-0,32 %) Bitcoin EUR
40 310,02 -428,66 (-1,05 %)
MRK Jan 2026 125.000 call
| Clôture précédente | 6,50 |
| Ouverture | 6,50 |
| Offre | 5,05 |
| Vente | 6,50 |
| Prix d’exercice | 125,00 |
| Date d’expiration | 2026-01-16 |
| Var. jour | 6,50 - 6,50 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 19 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
